Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders
In this multi-center, randomized, open label phase-3 study, the correction of mild or
moderate anemia and the effect on iron kinetics by rHuEPO treatment, with or without
intravenous iron treatment, in patients with LPD not receiving antineoplastic therapy will
LENGTH OF STUDY 16 weeks
NUMBER OF CENTERS 15
NUMBER OF SUBJECTS 66
STRATIFICATION 1. According to diagnosis; CLL and indolent NHL vs. MM. 2. According to level
of S-epo > 100 IU/L vs £ 100 IU/L at baseline.
TREATMENT The patients will be randomized to receive 30 000 IU Neorecormon â (epoetin beta)
s.c. once / week for 16 consecutive weeks +/- 100mg/week of Venofer â (iron sucrose) from
week 0 to 6, followed by one 100mg dose every 2 week from weeks 8 until 14.
If the increase in Hb concentration is less than 10g/L from baseline (week 0) until week 4
weeks, the dose of epoetin beta will be increased to 60 000 IU weekly from week 5.
If the Hb concentration exceeds 140 g/L, the epoetin beta therapy will be suspended. The
treatment will be resumed once the Hb concentration falls below 130 g/L. This resumed dose
will be 75% of the previous dose (e.g. if the previous dose was 30 000 IU before suspension,
the continued dose should be 22 500 IU. If the dose was 60 000 IU before suspension, the
dose should be 45 000 IU).
If the level of S-ferritin reaches >1000 ug/L iron sucrose should be suspended until the
S-ferritin level falls below 500 ug/L.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To compare the mean change in hemoglobin (Hb) concentrations from baseline to EOT (End of treatment ) between the two treatment groups.
Michael Hedenus, MD
Sweden: Medical Products Agency